Colorectal Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Colorectal Cancer pipeline constitutes key companies continuously working towards developing Colorectal Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Colorectal Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Colorectal Cancer Market.

The Colorectal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Colorectal Cancer Pipeline Report: https://www.delveinsight.com/report-store/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Colorectal Cancer treatment therapies with a considerable amount of success over the years.
• Colorectal Cancer companies working in the treatment market are Processa Pharmaceuticals, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Gritstone Bio, Inc., G1 Therapeutics, Amgen, Mirati Therapeutics, and others, are developing therapies for the Colorectal Cancer treatment
• Emerging Colorectal Cancer therapies such as - PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others are expected to have a significant impact on the Colorectal Cancer market in the coming years.
• In October 2020, G1 Therapeutics initiated a Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Colorectal Cancer. Patients will be randomly assigned (1:1) to receive placebo or trilaciclib on Days 1 and 2 administered intravenously (IV) prior to FOLFOXIRI/bevacizumab in 14-day cycles for up to 12 cycles (Induction)
• In March 2022, ALX Oncology Inc. in collaboration with Merck Sharp & Dohme Corp. and Eli Lilly and Company will initiate a Phase II Study (With Safety run-in) of ALX148 in Combination with Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Colorectal Cancer

Colorectal Cancer Overview
Colorectal Cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any cancer that affects the colon and rectm. Colorectal cancer occurs when tumors form in the lining of the large intestine. It is common in both men and women. The risk of developing colorectal cancer rises after age 50.

Get a Free Sample PDF Report to know more about Colorectal Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Colorectal Cancer Drugs Under Different Phases of Clinical Development Include:
• 188RNL-BAM: Plus Therapeutics
• PCS11T: Processa Pharmaceuticals
• Adagrasib: Mirati Therapeutics
• HLX13: Shanghai Henlius Biotech
• XL092: Exelixis
• Geptanolimab: Apollomics
• Etrumadenant: Arcus Biosciences
• EO2040: Enterome
• HDM201: Novartis Pharmaceuticals]
• LYL845: Lyell Immunopharma
• TP-1454: Sumitomo Pharma Oncology
• NT219: Purple Biotech Ltd.
• NKTR-255: Nektar Therapeutics
• Evorpacept (ALX148): ALX Oncology Inc.
• CPGJ 602: Sunshine Guojian Pharmaceutical
• Trastuzumab deruxtecan : Daiichi Sankyo
• GRT-C901: Gritstone Bio, Inc.
• SHR-1701: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
• Trilaciclib: G1 Therapeutics
• Lumakras (sotorasib): Amgen
• MRTX849 Mirati Therapeutics


Route of Administration
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy


Colorectal Cancer Pipeline Therapeutics Assessment
• Colorectal Cancer Assessment by Product Type
• Colorectal Cancer By Stage and Product Type
• Colorectal Cancer Assessment by Route of Administration
• Colorectal Cancer By Stage and Route of Administration
• Colorectal Cancer Assessment by Molecule Type
• Colorectal Cancer by Stage and Molecule Type

DelveInsight's Colorectal Cancer Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Colorectal Cancer product details are provided in the report. Download the Colorectal Cancer pipeline report to learn more about the emerging Colorectal Cancer therapies at:
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Colorectal Cancer Therapeutics Market include:
Key companies developing therapies for Colorectal Cancer are - Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, and others.

Colorectal Cancer Pipeline Analysis:
The Colorectal Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Colorectal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Colorectal Cancer Treatment.
• Colorectal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Colorectal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Colorectal Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Colorectal Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Colorectal Cancer Pipeline Market Drivers
• Emergence of targeted therapies for mCRC treatment, Technical Advancement in molecular subtyping of CRC tumors, Increase in product development activities, are some of the important factors that are fueling the Colorectal Cancer Market.

Colorectal Cancer Pipeline Market Barriers
• However, Limitations in understanding secondary resistance, High Cost of Treatment, Challenges related to precision oncology in mCRC management, and other factors are creating obstacles in the Colorectal Cancer Market growth.

Scope of Colorectal Cancer Pipeline Drug Insight
• Coverage: Global
• Key Colorectal Cancer Companies: Processa Pharmaceuticals, Shanghai Henlius Biotech, Apollomics, Novartis Pharmaceuticals, Sumitomo Pharma Oncology, Purple Biotech Ltd., Nektar Therapeutics, ALX Oncology Inc., Sunshine Guojian Pharmaceutical, Daiichi Sankyo, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Gritstone Bio, Inc., G1 Therapeutics, Amgen, Mirati Therapeutics, and others
• Key Colorectal Cancer Therapies: PCS11T, HLX13, Geptanolimab, HDM201, TP-1454, NT219, NKTR-255, Evorpacept (ALX148), CPGJ 602, Trastuzumab deruxtecan, GRT-C901, SHR-1701, Trilaciclib, Lumakras (sotorasib), MRTX849, and others
• Colorectal Cancer Therapeutic Assessment: Colorectal Cancer current marketed and Colorectal Cancer emerging therapies
• Colorectal Cancer Market Dynamics: Colorectal Cancer market drivers and Colorectal Cancer market barriers

Request for Sample PDF Report for Colorectal Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/colorectal-cancer-crc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Colorectal Cancer Report Introduction
2 Colorectal Cancer Executive Summary
3 Colorectal Cancer Overview
4 Colorectal Cancer- Analytical Perspective In-depth Commercial Assessment
5 Colorectal Cancer Pipeline Therapeutics
6 Colorectal Cancer Late Stage Products (Phase II/III)
7 Colorectal Cancer Mid Stage Products (Phase II)
8 Colorectal Cancer Early Stage Products (Phase I)
9 Colorectal Cancer Preclinical Stage Products
10 Colorectal Cancer Therapeutics Assessment
11 Colorectal Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Colorectal Cancer Key Companies
14 Colorectal Cancer Key Products
15 Colorectal Cancer Unmet Needs
16 Colorectal Cancer Market Drivers and Barriers
17 Colorectal Cancer Future Perspectives and Conclusion
18 Colorectal Cancer Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Colorectal Cancer Market
https://www.delveinsight.com/report-store/colorectal-cancer-crc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Colorectal Cancer-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Colorectal Cancer Epidemiology
https://www.delveinsight.com/report-store/colorectal-cancer-crc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Colorectal Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.